Teva Announces Prescription Copay Savings Program for Generic Gleevec® Tablets in the United States
November 15 2017 - 2:19PM
Business Wire
People who meet certain requirements are
eligible to participate and may pay as little as $0
out-of-pocket
Teva Pharmaceuticals USA, a subsidiary of Teva Pharmaceutical
Industries Ltd., (NYSE and TASE: TEVA) today announced the launch
of a prescription copay assistance program in the U.S. for the
Company's generic equivalent to Gleevec®1 (imatinib mesylate)
tablets. Teva launched imatinib mesylate tablets in the U.S.
earlier this year.
People who meet certain requirements are eligible to participate
in the program and may pay as little as $0 out-of-pocket with a
maximum benefit of up to $700 per fill. The program applies to
eligible patients who are commercially insured. Savings are limited
to copay amount and eligibility restrictions, terms and conditions
apply.
In compliance with applicable laws and regulations, the program
is not available to patients who are covered under Medicaid,
Medicare, a Medicare Part D or Medicare Advantage plan (regardless
of whether a specific prescription is covered), TRICARE, CHAMPUS,
Government Health Insurance Plan ("Healthcare Reform"), or any
other state or federal medical or pharmaceutical benefit program or
pharmaceutical assistance program.
“This effort further reinforces Teva’s long-standing commitment
to providing access to our medicines," said Andy Boyer, President
& CEO, Global Generic Medicines, North America at Teva. "Given
today's economic climate, programs that help alleviate the high
copay costs that many patients face are increasingly
important."
Eligible patients can enroll in the program and receive
additional information about copay assistance by visiting
www.TevaImatinibSavings.com or calling 1-844-546-8639.
Teva remains committed to strengthening its generics business
with continued investment in new and diverse, high quality
products. With nearly 600 generic medicines available, Teva has the
largest portfolio of FDA-approved generic products on the market
and holds the leading position in first-to-file opportunities, with
over 100 pending first-to-files in the U.S. Currently, one in seven
generic prescriptions dispensed in the U.S. is filled with a Teva
generic product.
About Teva
Teva Pharmaceuticals USA, Inc., a wholly-owned subsidiary of
Israeli-based Teva Pharmaceutical Industries Ltd., the global
leader in generics and one of the leading pharmaceutical companies
in the world. Teva's extensive U.S. operations are headquartered
near Philadelphia, PA. Teva Generics leverages its portfolio of
more than 1,800 molecules to produce a wide range of generic
products in nearly every therapeutic area. For more information,
visit www.tevausa.com.
Cautionary Note Regarding Forward-Looking Statements
This press release contains forward-looking statements within
the meaning of the Private Securities Litigation Reform Act of 1995
, which are based on management’s current beliefs and expectations
and are subject to substantial risks and uncertainties, both known
and unknown, that could cause our future results, performance or
achievements to differ significantly from that expressed or implied
by such forward-looking statements. Important factors that could
cause or contribute to such differences include risks relating
to:
- commercial success of Teva's generic
version of imatinib mesylate;
- our generics medicines business,
including: that we are substantially more dependent on this
business, with its significant attendant risks, following our
acquisition of Allergan plc’s worldwide generic pharmaceuticals
business (“Actavis Generics”); our ability to realize the
anticipated benefits of the acquisition (and any delay in realizing
those benefits) or difficulties in integrating Actavis Generics;
the increase in the number of competitors targeting generic
opportunities and seeking U.S. market exclusivity for generic
versions of significant products; price erosion relating to our
generic products, both from competing products and as a result of
increased governmental pricing pressures; and our ability to take
advantage of high-value biosimilar opportunities;
- our business and operations in general,
including: uncertainties relating to our recent senior management
changes; our ability to develop and commercialize additional
pharmaceutical products; manufacturing or quality control problems,
which may damage our reputation for quality production and require
costly remediation; interruptions in our supply chain; disruptions
of our or third party information technology systems or breaches of
our data security; the failure to recruit or retain key personnel,
including those who joined us as part of the Actavis Generics
acquisition; the restructuring of our manufacturing network,
including potential related labor unrest; the impact of continuing
consolidation of our distributors and customers; variations in
patent laws that may adversely affect our ability to manufacture
our products; adverse effects of political or economic instability,
major hostilities or terrorism on our significant worldwide
operations; and our ability to successfully bid for suitable
acquisition targets or licensing opportunities, or to consummate
and integrate acquisitions; and
- compliance, regulatory and litigation
matters, including: costs and delays resulting from the extensive
governmental regulation to which we are subject; the effects of
reforms in healthcare regulation and reductions in pharmaceutical
pricing, reimbursement and coverage; potential additional adverse
consequences following our resolution with the U.S. government of
our FCPA investigation; governmental investigations into sales and
marketing practices; potential liability for sales of generic
products prior to a final resolution of outstanding patent
litigation; product liability claims; increased government scrutiny
of our patent settlement agreements; failure to comply with
complex Medicare and Medicaid reporting and payment
obligations; and environmental risks.
and other factors discussed in our Annual Report on Form 20-F
for the year ended December 31, 2016 (“Annual Report”)
and in our other filings with the U.S. Securities and Exchange
Commission (the “SEC”). Forward-looking statements speak only
as of the date on which they are made, and we assume no obligation
to update or revise any forward-looking statements or other
information contained herein, whether as a result of new
information, future events or otherwise. You are cautioned not to
rely on these forward-looking statements. You are advised to
consult any additional disclosures we make in our reports to
the SEC on Form 6-K, as well as the cautionary discussion of
risks and uncertainties under “Risk Factors” in our Annual Report.
These are factors that we believe could cause our actual results to
differ materially from expected results. Other factors besides
those listed could also materially and adversely affect us. This
discussion is provided as permitted by the Private Securities
Litigation Reform Act of 1995.
1 GLEEVEC® is a registered trademark of Novartis Oncology.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20171115006311/en/
Teva Pharmaceuticals USA, Inc.PR Contacts:United StatesDenise
Bradley, 215-591-8974orElizabeth DeLuca,
484-612-5407
Teva Pharmaceutical Indu... (NYSE:TEVA)
Historical Stock Chart
From Mar 2024 to Apr 2024
Teva Pharmaceutical Indu... (NYSE:TEVA)
Historical Stock Chart
From Apr 2023 to Apr 2024